PEG-uricase in the management of treatment-resistant gout and hyperuricemia

Sherman, Merry R.; Saifer, Mark G.P.; Pérez-Ruiz, Fernando

doi:10.1016/j.addr.2007.06.011

Cited by 251 publications

(158 citation statements)

References 57 publications

Supporting

Mentioning

152

Contrasting

Unclassified

Order By: Relevance

“…Unfortunately, although licenced in the UK, it was rejected by NICE due to high cost. [33][34][35] Pegloticase causes extreme urate reduction and can, therefore, be useful in refractory gout or for 'debulking' significant tophaceous disease before switching to a longer-term maintenance agent.…”

Section: Rasburicasementioning

confidence: 99%

Current treatment options for acute and chronic gout

Jordan¹,

Jeffries²

2014

Prescriber

View full text Add to dashboard Cite

show abstract

Section: Rasburicasementioning

confidence: 99%

Current treatment options for acute and chronic gout

Jordan¹,

Jeffries²

2014

Prescriber

View full text Add to dashboard Cite

show abstract

“…1 Hyperuricaemia causes an accumulation of monosodium urate crystals, which are deposited in the supersaturated body fluids and then are deposited in tissues and around joints during the asymptomatic hyperuricaemic gout stage. 1,2,6 The monosodium urate crystals form tophi. 1,2 The tophi cause inflammation, which leads to the symptoms of an acute gouty attack.…”

Section: Pathophysiologymentioning

confidence: 99%

“…1,2 The tophi cause inflammation, which leads to the symptoms of an acute gouty attack. 2,6 The presence of tophi can lead to soft tissue damage and destruction of the afflicted joint, which can cause the deformities associated with gout. 1 However, it is important to note that, while hyperuricaemia is a risk factor for gout, not all patients with hyperuricaemia develop gout.…”

Section: Pathophysiologymentioning

confidence: 99%

“…7 Uricase, namely polyethylene glycol-linked uricase, is being investigated in Phase 3 clinical trials in order to determine whether it is effective in controlling hyperuricaemic patients with chronic gout, and patients who have not responded to conventional therapy. 6,7 Long-term hypouricaemic therapy is intended to decrease levels of serum uric acid in order to decrease acute gout attacks, while at the same time preventing damage over time to the patient's joints by decreasing the size and amount of tophi. 2 …”

Section: Allopurinolmentioning

confidence: 99%

“…2 The search for new gout treatments has increased considerably due to the large increase in the incidence of gout, as well as the renal and cardiovascular consequences of this disease. 6 …”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Hyperuricaemia and gout: A review

Kopke

Greeff

2010

South African Family Practice

View full text Add to dashboard Cite

Gout is a painful, inflammatory disease that affects more men than women. The incidence of gout has increased substantially over the past few decades, as evidenced by information from the Rochester project. Some of the risk factors for the development of gout include: increased ethanol intake, high dietary purine consumption, obesity and the use of certain drugs, such as diuretics. Another important risk factor for the development of gout is hyperuricaemia.Hyperuricaemia results from an imbalance between the rate of production and excretion of uric acid in the body. An excess of uric acid thus builds up in the body, supersaturating body fluids and leading to the formation of monosodium urate crystals. These crystals accumulate in tissue and around joints, leading to an acute gout attack.Gout can be divided into four phases, namely asymptomatic hyperuricaemia, acute gout attacks or recurrent gout, intercritical gout and chronic tophaceous gout. Various treatment options are available for gout, and the treatment for each gout patient is determined by the stage of the disease. Non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, corticotropin and colchicine are used for the treatment of acute gout attacks. Allopurinol and probenecid are used for long-term hypouricaemic therapy, while NSAIDs and colchicine are prescribed for the prophylaxis of future gout attacks.All of these treatments have side effects, ranging from mild to life-threatening in nature. There is a need for novel gout therapies that have fewer side effects but are still as effective.Peer reviewed.

show abstract